. The typical presentation of the non-salt-losing forms is premature pubarche in both sexes.
The molecular etiology of 3β-HSD deficiency lies in a defect in the HSD3B2 gene, coding for the isoform II of the enzyme (type 2) .
Case Report
A healthy full-term female neonate, born to a non-consanguineous couple from Eastern Switzerland, was admitted to our pediatric endocrine service on day 8 of life for further evaluation of increased 17OHP in newborn screening. She presented in no physical distress, feeding well and gaining weight appropriately.
On clinical examination, we found normal female external genitalia without virilization or palpable gonads. Ultrasound revealed female internal genitalia with a slightly stimulated uterus and normal ovaries with few follicles. Biochemical analyses revealed increased adrenocorticotropic hormone with low cortisol, increased 17OHP, normal DHEA, 11-deoxycortisol, and increased renin ( table 1 ) .
For suspected CAH with glucocorticoid deficiency, the patient was started on hydrocortisone (HC) immediately. The following day, she developed salt loss (Na 129 mmol/l, K 6.1 mmol/l) and was therefore also started on fludrocortisone (FC) and NaCl supplements ( table 1 ) . On continuous HC and FC replacement, psychomotor and physical development was normal.
At 7 months of age, the patient was admitted to the hospital for further evaluation: HC and FC were discontinued. Serum steroids were measured 36 h after the last dose of HC and FC. Results confirmed glucocorticoid and mineralocorticoid deficiency ( table 1 ) . However, there was no increase in 17OHP or androgens. Due to the severe lack of all steroid hormones, we suspected a defect high up in the steroid cascade.
Results

Genetic Analysis
Genetic analysis revealed that the patient was compound heterozygous for 2 mutations in the HSD3B2 gene ( fig. 1 A) . One mutation (c.503delC) caused a frameshift leading to a premature stop codon (A168Vfs * 6). The other was a nonsense (stop) mutation shortly after the first one (c.512G>A; W171X). The combination of both mutations was considered to cause the phenotype of the patient.
Both mutations lead to a shorter and aberrant gene product. The normal peptide product is 285 amino acids long, whereas the frameshift A168Vfs * 6 mutation coded for a peptide of 172 amino acids and the stop W171X mutation for a 170 amino acid peptide ( fig. 1 B) . The parents were heterozygous for the 2 mutations ( fig. 1 A) . Two years later, a brother was born with normal male external genitalia and a normal urinary steroid profile at birth. The genetic analysis showed that he was heterozygous for the A168Vfs * 6 paternal mutation ( fig. 1 A) .
In silico Analysis
The 2 mutations were further analyzed in silico. We analyzed the human HSD3B2 peptide residues 167-173 involved in the mutations by sequence alignment ( fig. 2 ) and structural modeling ( fig. 3 ). The 2 mutations were checked by comparing the positions of these amino acids in different mammalian HSD3B sequences ( fig. 2 A) . gene of the patient were detected. One was a 1-bp deletion responsible for a shift of the reading frame causing 5 amino acid changes followed by a stop codon (c.503delC; A168Vfs * 6). The other mutation, only 9 nucleotides downstream, was a 1-bp change which produced a stop codon (c.512G>A; W171X). The parents presented 1 mutation each and the younger brother the paternal mutation. The HSD3B2 gene was amplified (exonic coding sequences including intronic boundaries) using specific primers and PCR amplification protocols as described elsewhere. Obtained sequences were compared to NG_013349.1 (http://www.ncbi.nlm.nih. gov/). B The HSD3B2 gene alleles of the patient code for 2 different peptide sequences, both shorter than the wild type. Partial sequence alignment and secondary structure prediction of the HSD3B2 protein. A Human HSD3B2 was partially aligned with homologous sequences from 6 mammalian species. Position A168 is conserved among different species, whereas position W171 is replaced with S171 in mouse and rat. The alignment of the HSD3B2 amino acid sequence (P26439) was adapted from the UniProt database, and the other mammalian sequences were also available in the same database (www.uniprot.org). Human: Homo sapiens; Canfa: dog, Canis familiaris ; Pig: Sus scrofa ; Bovine: cattle, Bos taurus ; Mouse: Mus musculus ; Rat: Rattus norvegicus; Macmu: Rhesus macaque, Macaca mulatta . B Prediction of the secondary structure of the HSD3B2 protein. The positions of A168Vfs * 6 and W171X and previously reported mutations are highlighted. All these mutations are close to the alpha helix and coil region predicted with the confidence value (depicted in line 3). W171 and L173 are predicted to be located in a disordered region, indicated by question marks. Prediction of the secondary structure was obtained from the Phyre2 server [Kelley and Sternberg, 2009] . The first line indicates the amino acid sequence and the second line the secondary structure prediction.
Amino acid A168 is well conserved across all the species, but tryptophan at position 171 is substituted with serine in mouse and rat species ( fig. 2 A) . The structural studies showed that amino acids 167-173 are located in the alpha helix and coil region of the protein and are close to the active site and NAD-binding site of the HSD3B2 protein ( fig. 3 ) . We suggest that the A168Vfs * 6 and W171X mutations lead to truncated HSD3B2 proteins without enzymatic activity. Other previously reported mutations, A167V and L173R, are located in the vicinity of our patient's mutations ( fig. 3 ) , A167V not having a major effect on the native structure of HSD3B2 [Nayak et al., 1998; Moisan et al., 1999] , whereas heterozygous L173R reduced 3β-HSD enzyme activity by half [Russell et al., 1994; Moisan et al., 1999] . Our analysis predicted that L173R is located in a disordered region of the protein ( fig. 2 B) .
Discussion
We describe a patient with a novel HSD3B2 mutation (A168Vfs * 6) and a previously reported one (W171X). The latter (maternal mutation) was described 20 years ago in 2 families also from Eastern Switzerland [Rheaume et al., 1992] . We were able to track medical records and suspect a familial relation. Patients in these families, who carried the mutation in a homozygous fashion, presented with a classic form of 3β-HSD deficiency with severe salt wasting.
Our female patient was diagnosed with severe glucocorticoid and mineralocorticoid deficiency in newborn screening due to elevated 17OHP. The lack of androgens as well as the completely normal female genitalia made us suspect a defect high up in the steroid cascade. By molecular analysis, our patient could be diagnosed with a compound heterozygous HSD3B2 defect. The increase in 17OHP could be interpreted as a product of placental activity of the isoform I of 3β-HSD. Surprisingly, DHEA was not elevated at birth or at 7 months after discontinuation of treatment, probably due to the remaining activity of 3β-HSD I or to the conversion in the periphery also of 3β-HSD I. We expect an increase in DHEA during adrenarche with otherwise absent increase in steroid hormones and lack of spontaneous pubertal development.
Conclusion
In a female CAH patient without virilization, 3β-HSD II deficiency must be considered. 17OHP can be elevated in the first few days of life due to placental and peripheral 3β-HSD I activity. DHEA is not necessarily increased.
We report a novel HSD3B2 mutation, c.503delC, clinically causing a severe impairment of 3β-HSD II activity and leading to a nearly complete deficiency in glucocorticoids, mineralocorticoids, and sex steroids in our phenotypically non-virilized female CAH patient. . The 3D model structure was obtained using the HSD3B2 protein (NP_000189.1, P26439) sequence. We obtained the HSD3B2 structural model (based on clz45A) from the Phyre2 server [Kelley and Sternberg, 2009] , which was visualized by the YASARA program (www.yasara.org).
